• 1. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 2. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Chlorobenzenes

Research Brief on 2-(4-chlorophenyl)ethylhydrazine (CAS: 25198-48-5) in Chemical Biology and Pharmaceutical Applications

2-(4-chlorophenyl)ethylhydrazine (CAS: 25198-48-5) is a hydrazine derivative with significant potential in chemical biology and pharmaceutical research. Recent studies have highlighted its role as a versatile building block in the synthesis of bioactive compounds, particularly in the development of enzyme inhibitors and receptor modulators. This research brief synthesizes the latest findings on this compound, focusing on its chemical properties, biological activities, and therapeutic applications.

Recent investigations into 2-(4-chlorophenyl)ethylhydrazine have explored its utility in the design of monoamine oxidase (MAO) inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit selective inhibition of MAO-B, an enzyme implicated in neurodegenerative disorders such as Parkinson's disease. The study utilized molecular docking simulations and in vitro assays to elucidate the structure-activity relationship, revealing that the chlorophenyl moiety enhances binding affinity to the MAO-B active site.

In addition to its neurological applications, 2-(4-chlorophenyl)ethylhydrazine has shown promise in oncology research. A 2022 paper in Bioorganic & Medicinal Chemistry Letters reported its incorporation into novel histone deacetylase (HDAC) inhibitors. The researchers synthesized a series of hydrazide-hydrazone derivatives, with 2-(4-chlorophenyl)ethylhydrazine serving as a key structural component. These compounds demonstrated potent antiproliferative effects against several cancer cell lines, with IC50 values in the low micromolar range.

The compound's chemical stability and reactivity have also been subjects of recent investigation. A 2023 study in Tetrahedron Letters examined its behavior under various reaction conditions, establishing optimal parameters for its use in multicomponent reactions. The researchers noted that the presence of the chlorophenyl group significantly influences the compound's electronic properties, making it particularly useful in nucleophilic substitution reactions.

From a pharmacological perspective, pharmacokinetic studies of 2-(4-chlorophenyl)ethylhydrazine derivatives have yielded important insights. Research published in European Journal of Pharmaceutical Sciences (2023) employed in silico ADMET prediction tools and in vivo experiments to evaluate the drug-likeness of these compounds. The results indicated favorable absorption profiles and moderate blood-brain barrier penetration, supporting their potential as central nervous system-targeting agents.

Ongoing research continues to explore novel applications of 2-(4-chlorophenyl)ethylhydrazine. Current clinical investigations are examining its derivatives as potential treatments for mood disorders, leveraging its ability to modulate serotonin and dopamine levels. Furthermore, its use in radiopharmaceutical development is being investigated, with preliminary studies showing promise in PET tracer synthesis.

In conclusion, 2-(4-chlorophenyl)ethylhydrazine (CAS: 25198-48-5) represents a valuable scaffold in medicinal chemistry with diverse therapeutic applications. Recent advances in understanding its structure-activity relationships and biological effects have positioned it as a compound of significant interest for future drug discovery efforts. Continued research into its derivatives and mechanisms of action is expected to yield important contributions to multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)